Viridian Therapeutics, Inc. (VRDN) Ownership
VRDN ownership summary
as of October 18, 2026- Institutions
- 126.8% of shares outstanding
- Insiders
- 0.17% of shares outstanding
- Shares outstanding
- 113.3M
- Float
- 100.8M shares available to trade
- Short interest
- 16.43% 18.0M shares short
- Days to cover
- 10.90 short interest down 7.7% vs prior month
- Institutions 126.78%
- Insiders 0.17%
VRDN top institutional holders
20 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | FMR Inc | 14.66% | 16.6M | $316.0M | +1.2M (+8.0%) | June 30, 2026 |
| 2 | BlackRock Inc | 7.55% | 8.6M | $162.7M | +720,013 (+9.2%) | June 30, 2026 |
| 3 | Bellevue Group AG | 5.94% | 6.7M | $128.1M | +5,765 (+0.1%) | June 30, 2026 |
| 4 | Paradigm Biocapital Advisors LP | 5.93% | 6.7M | $128.0M | +3.6M (+113.5%) | June 30, 2026 |
| 5 | Kynam Capital Management, LP | 5.70% | 6.5M | $122.8M | +4.1M (+175.6%) | June 30, 2026 |
| 6 | State Street Corp | 5.41% | 6.1M | $116.6M | +1.5M (+31.1%) | June 30, 2026 |
| 7 | T. Rowe Price Associates, Inc. | 5.07% | 5.7M | $109.4M | +2.5M (+79.3%) | June 30, 2026 |
| 8 | Fairmount Funds Management LLC | 4.49% | 5.1M | $96.9M | +1.2M (+30.1%) | June 30, 2026 |
| 9 | Vanguard Capital Management, LLC | 4.04% | 4.6M | $87.1M | +409,659 (+9.8%) | June 30, 2026 |
| 10 | Deep Track Capital, LP | 3.17% | 3.6M | $68.4M | +2.2M (+157.7%) | June 30, 2026 |
| 11 | VR Adviser, LLC | 2.88% | 3.3M | $62.0M | −624,792 (−16.1%) | June 30, 2026 |
| 12 | Wellington Management Company LLP | 2.76% | 3.1M | $59.5M | +49,808 (+1.6%) | June 30, 2026 |
| 13 | Vanguard Portfolio Management, LLC | 2.43% | 2.8M | $52.4M | +1.1M (+67.7%) | June 30, 2026 |
| 14 | Geode Capital Management, LLC | 2.21% | 2.5M | $47.6M | +168,656 (+7.2%) | June 30, 2026 |
| 15 | venBio Select Advisor LLC | 2.21% | 2.5M | $47.6M | +1.0M (+66.7%) | June 30, 2026 |
| 16 | Baker Bros Advisors LP | 2.10% | 2.4M | $45.3M | +411,347 (+20.9%) | June 30, 2026 |
| 17 | Point72 Asset Management, L.P. | 2.07% | 2.3M | $44.6M | +2.0M (+625.8%) | June 30, 2026 |
| 18 | Caligan Partners LP | 1.94% | 2.2M | $41.8M | +2.2M (0.0%) | June 30, 2026 |
| 19 | Novo A/S | 1.88% | 2.1M | $40.6M | +135,000 (+6.8%) | June 30, 2026 |
| 20 | TANG CAPITAL MANAGEMENT LLC | 1.58% | 1.8M | $34.1M | — | June 30, 2026 |
Value at the latest close. Change = shares bought or sold in the latest quarterly filing (13F). In the top 20, 18 holders added 24.5M shares and 1 cut 625K.
VRDN top mutual fund and ETF holders
20 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | Vanguard MStar Total Stk Mkt Idx Invest | 2.96% | 3.3M | $63.7M | −7,369 (−0.2%) | August 31, 2026 |
| 2 | iShares Russell 2000 ETF | 2.29% | 2.6M | $49.3M | −29,824 (−1.1%) | September 30, 2026 |
| 3 | State Street® SPDR® S&P® Biotech ETF | 2.22% | 2.5M | $47.8M | −48,000 (−1.9%) | September 30, 2026 |
| 4 | Fidelity Advisor Biotechnology I | 1.57% | 1.8M | $33.9M | — | August 31, 2026 |
| 5 | Fidelity Select Health Care | 1.32% | 1.5M | $28.5M | — | August 31, 2026 |
| 6 | Strategic Advisers Fidelity US TtlStk | 1.23% | 1.4M | $26.6M | +10,091 (+0.7%) | August 31, 2026 |
| 7 | Fidelity Select Biotechnology | 1.15% | 1.3M | $24.9M | — | August 31, 2026 |
| 8 | Fidelity Small Cap Growth | 1.12% | 1.3M | $24.1M | — | July 31, 2026 |
| 9 | T. Rowe Price New Horizons | 1.09% | 1.2M | $23.4M | −50,300 (−3.9%) | August 31, 2026 |
| 10 | T. Rowe Price Health Sciences | 1.08% | 1.2M | $23.2M | −226,200 (−15.6%) | August 31, 2026 |
| 11 | MEDICAL BioHealth EUR Acc | 0.98% | 1.1M | $21.2M | +236 (+0.0%) | August 31, 2026 |
| 12 | Fidelity Stock Selector Small Cap | 0.96% | 1.1M | $20.7M | +30,248 (+2.9%) | July 31, 2026 |
| 13 | Fidelity Small Cap Index | 0.87% | 987K | $18.8M | +8,511 (+0.9%) | July 31, 2026 |
| 14 | Vanguard Explorer Inv | 0.85% | 960K | $18.3M | +527,428 (+121.8%) | June 30, 2026 |
| 15 | T. Rowe Price Integrated US Sm Gr Eq | 0.76% | 856K | $16.3M | — | August 31, 2026 |
| 16 | iShares Russell 2000 Value ETF | 0.74% | 840K | $16.0M | +1,274 (+0.2%) | September 30, 2026 |
| 17 | Fidelity Series Small Cap Opps | 0.70% | 792K | $15.1M | +19,304 (+2.5%) | July 31, 2026 |
| 18 | Fidelity Advisor Health Care I | 0.67% | 760K | $14.5M | — | August 31, 2026 |
| 19 | Vanguard Strategic Equity Inv | 0.66% | 749K | $14.3M | +479,757 (+178.0%) | June 30, 2026 |
| 20 | Fidelity Advisor New Insights I | 0.58% | 660K | $12.6M | — | August 31, 2026 |
Funds report holdings monthly or quarterly; dates differ by fund.
VRDN insider transactions
latest 2| Date | Name | Transaction | Price | Shares | Value |
|---|---|---|---|---|---|
| 2025-12-31 | Jennifer Tousignant | Sell | $31.16 | 2,272 | $70,796 |
| 2025-10-23 | Fairmount Funds Management Llc | Buy | $22.00 | 454,545 | $10.0M |
Reported trades by company officers, directors and other filers (including disclosures by members of Congress where EODHD lists them). "—" where the filing gives no share count.
VRDN shares outstanding
Year-end shares outstanding, adjusted for splits.
Who owns VRDN
Institutional investors own 126.8% of Viridian Therapeutics's shares and insiders 0.17%. The largest holder is FMR Inc with 14.66% of the shares (16.6M), as of June 30, 2026. Among the top 20 institutions, 18 added shares and 1 reduced their stake in the latest filings. Short interest is 16.43% of the float, or 10.90 days of average trading volume. The share count rose 21,858.4% since 2014.
Related: VRDN analyst forecast, VRDN key metrics. See the VRDN stock overview for the latest quote and news.
VRDN ownership FAQ
Who owns the most Viridian Therapeutics stock?
The largest shareholders of Viridian Therapeutics are FMR Inc (14.66%), BlackRock Inc (7.55%), Bellevue Group AG (5.94%), Paradigm Biocapital Advisors LP (5.93%), Kynam Capital Management, LP (5.70%).
What percentage of Viridian Therapeutics is owned by institutions?
Institutions hold 126.8% of Viridian Therapeutics's shares outstanding; insiders hold 0.17%.
Which funds own Viridian Therapeutics?
The largest fund holders of Viridian Therapeutics are Vanguard MStar Total Stk Mkt Idx Invest (2.96%), iShares Russell 2000 ETF (2.29%), State Street® SPDR® S&P® Biotech ETF (2.22%), Fidelity Advisor Biotechnology I (1.57%), Fidelity Select Health Care (1.32%).
What is Viridian Therapeutics's short interest?
18.0M shares of Viridian Therapeutics were sold short, 16.43% of the float; at the average daily volume it would take 10.90 days to cover.
Are insiders buying or selling Viridian Therapeutics?
Of the latest 2 reported insider transactions in Viridian Therapeutics (since October 23, 2025), 1 were purchases and 1 were sales.
How many shares of Viridian Therapeutics are outstanding?
Viridian Therapeutics has 113.3M shares outstanding, of which 100.8M are in the public float.